RecruitingInterventionalPhase 2

Groningen International Study on Sentinel Nodes in Vulvar Cancer-III, a Prospective Phase II Treatment Trial

NCT ID: NCT05076942Sponsor: University Medical Center GroningenLast updated: 2023-08-01

Summary

Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.

Detailed description

Rationale: Standard treatment of early stage vulvar cancer is a wide local excision of the primary tumor combined with the sentinel node (SN) procedure for the groins. An inguinofemoral lymphadenectomy (IFL) is only indicated in case of a positive SN. An IFL is associated with major morbidity, e.g. wound healing problems, lymphoceles, lymphedema of the legs and recurrent infections. GROINSS-V II investigated whether radiotherapy would be a safe alternative for IFL in case of SN metastasis. The results for radiotherapy in the group with metastasis ≤ 2mm are promising. This study also showed that for metastasis \> 2mm, only radiotherapy was not efficient. The efficacy of treatment can be increased by adding chemotherapy or giving a higher dose of radiotherapy. GROINSS-V III will investigate this regimen. Objective: The primary objective of this study is to investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early stage vulvar cancer patients with a macrometastasis (\>2mm) and/or extracapsular extension in the SN. The secondary objective is to evaluate the short and long-term morbidity associated with the SN procedure and chemoradiation. Study design: Phase II treatment trial, with stopping rules for the incidence of groin recurrences. Study population: early-stage vulvar cancer patients with a metastasis \> 2mm in their SN, or more than one metastasis ≤ 2mm. Intervention: Participants will be treated with chemoradiation, in a total dose of 56Gy to the involved site, combined with weekly cisplatin 40mg/m2 Main study parameters/endpoints: The primary endpoint is the groin recurrence rate in the first 2 years after primary treatment. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: participants will be treated with chemoradiation during 5 weeks instead of surgical treatment. There is a risk that this treatment will not be as effective as surgical treatment, which may lead to more groin recurrences which are hard to treat. By continuously monitoring the groin recurrence rate the investigators will notice activation of the stopping rule as early as possible.

Arms & interventions

RadiationRadiotherapy combined with cisplatin
Inguinofemoral radiotherapy combined with weekly cisplatin
DrugCisplatin
Inguinofemoral radiotherapy combined with weekly cisplatin

Outcome measures

Primary

Groin recurrence rate
Groin recurrence in the groin with SN metastasis treated with chemoradiation
Time frame: Within first 2 years after primary treatment

Secondary

Treatment related morbidity
Time frame: First two years after primary treatment
Quality of life as assessed using EORTC-QLQc30
Time frame: First two year after primary treatment
Quality of life-vulvar cancer specific, as assessed using VU34
Time frame: First two year after primary treatment

Eligibility criteria

Sex: FemaleAge: 18 Years and olderHealthy volunteers: No

Inclusion Criteria: * Histological confirmed primary SCC of the vulva * T1 tumor, not encroaching urethra/vagina/anus * Depth of invasion \> 1mm * Tumor diameter \< 4cm * Unifocal tumor * No enlarged (\>1.5cm) or suspicious inguinofemoral lymph nodes at imaging (CT/MRI/ultrasound) * Possibility to obtain informed consent * Metastatic sentinel lymph node; size of metastasis \> 2mm and / or extracapsular extension, or * Metastatic sentinel lymph node: more than 1 SN with metastasis ≤ 2mm * Patients are able to understand requirements of study, provide written informed consent and comply with the study and follow-up procedures * Adequate bone marrow, renal and liver function: * Absolute neutrophil count ≥ 1.5 x 109 /L * Platelet count ≥ 100 x 109 /L * Creatinine clearance ≥ 40 ml/min measured by the Cockroft Gault formula * Total bilirubin \< 1.25 x ULN Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN * Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale (Appendix A) * Age 18 years or older * Life expectancy of ≥ 12 weeks * Written informed consent Exclusion Criteria: * Inoperable tumors and tumors \> 4cm * Multifocal tumors * Tumors with other pathology than squamous cell carcinoma * Patients with enlarged / suspicious lymph nodes which are proven metastatic after fine needle aspiration cytology * No other carcinomas, other than basal cell carcinomas, within last 5 years * History of pelvic radiotherapy * History of any infection requiring hospitalization or antibiotics within 2 weeks before enrollment * Pregnant female or nursing mother * Desire to become pregnant * Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids * Unstable angina, myocardial infarction, cerebrovascular accident, \> Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure (see Appendix B) within 6 months before enrollment

Study locations (21)

UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, California, 92868

Recruiting

Krishnansu Tewari · Principal Investigator

Mount Sinai Medical Center

Miami Beach, Florida, 33140

Recruiting

Brian Slomovitz · Principal Investigator

Baystate Medical Center

Springfield, Massachusetts, 01199

Recruiting

Tashanna Myers · Principal Investigator

Spectrum Health at Butterworth Campus

Grand Rapids, Michigan, 49503

Recruiting

Kathleen Yost · Principal Investigator

Munson Medical Center

Traverse City, Michigan, 49684

Recruiting

Kathleen Yost · Principal Investigator

Nebraska Methodist Hospital

Omaha, Nebraska, 68114

Recruiting

Brent Tierney · Principal Investigator

Women's Cancer Center of Nevada

Las Vegas, Nevada, 89106

Recruiting

Nicola Spirtos · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting